Literature DB >> 30896606

Treating Biliary Atresia: The Challenge Continues.

Amar Nijagal1, Emily R Perito2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30896606      PMCID： PMC6430144          DOI： 10.1097/MPG.0000000000002302

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN： 0277-2116            Impact factor:   2.839


× No keyword cloud information.
  6 in total

Review 1.  Innate immunity of the newborn: basic mechanisms and clinical correlates.

Authors:  Ofer Levy
Journal:  Nat Rev Immunol       Date:  2007-05       Impact factor: 53.106

Review 2.  Pathogenesis of biliary atresia: defining biology to understand clinical phenotypes.

Authors:  Akihiro Asai; Alexander Miethke; Jorge A Bezerra
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-05-26       Impact factor: 46.802

3.  Newborn Bilirubin Screening for Biliary Atresia.

Authors:  Sanjiv Harpavat; Joseph A Garcia-Prats; Benjamin L Shneider
Journal:  N Engl J Med       Date:  2016-08-11       Impact factor: 91.245

4.  Use of corticosteroids after hepatoportoenterostomy for bile drainage in infants with biliary atresia: the START randomized clinical trial.

Authors:  Jorge A Bezerra; Cathie Spino; John C Magee; Benjamin L Shneider; Philip Rosenthal; Kasper S Wang; Jessi Erlichman; Barbara Haber; Paula M Hertel; Saul J Karpen; Nanda Kerkar; Kathleen M Loomes; Jean P Molleston; Karen F Murray; Rene Romero; Kathleen B Schwarz; Ross Shepherd; Frederick J Suchy; Yumirle P Turmelle; Peter F Whitington; Jeffrey Moore; Averell H Sherker; Patricia R Robuck; Ronald J Sokol
Journal:  JAMA       Date:  2014-05-07       Impact factor: 56.272

5.  A Phase I/IIa Trial of Intravenous Immunoglobulin Following Portoenterostomy in Biliary Atresia.

Authors:  Cara L Mack; Cathie Spino; Estella M Alonso; Jorge A Bezerra; Jeffrey Moore; Catherine Goodhue; Vicky L Ng; Saul J Karpen; Veena Venkat; Kathleen M Loomes; Kasper Wang; Averell H Sherker; John C Magee; Ronald J Sokol
Journal:  J Pediatr Gastroenterol Nutr       Date:  2019-04       Impact factor: 2.839

6.  High-dose IgG therapy mitigates bile duct-targeted inflammation and obstruction in a mouse model of biliary atresia.

Authors:  Erika K Fenner; Juri Boguniewicz; Rebecca M Tucker; Ronald J Sokol; Cara L Mack
Journal:  Pediatr Res       Date:  2014-04-11       Impact factor: 3.756
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.